Artelo Biosciences, Inc. (ARTL)

NASDAQ: ARTL · IEX Real-Time Price · USD
1.525
+0.015 (0.99%)
May 22, 2024, 3:58 PM EDT - Market closed
0.99%
Market Cap 4.92M
Revenue (ttm) n/a
Net Income (ttm) -9.60M
Shares Out 3.23M
EPS (ttm) -3.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,839
Open 1.497
Previous Close 1.510
Day's Range 1.497 - 1.525
52-Week Range 1.150 - 2.980
Beta 1.19
Analysts Strong Buy
Price Target 5.00 (+227.87%)
Earnings Date May 13, 2024

About ARTL

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indication... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ARTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ARTL stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target
$5.0
(227.87% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tre...

9 days ago - GlobeNewsWire

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...

12 days ago - GlobeNewsWire

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions Provides Further Evidence of Multiple Opportunities for Developm...

4 weeks ago - GlobeNewsWire

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tr...

4 weeks ago - GlobeNewsWire

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Major achievements in 2023 lay the foundation for key upcoming milestones Major achievements in 2023 lay the foundation for key upcoming milestones

2 months ago - GlobeNewsWire

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & Johnson ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leaders...

2 months ago - GlobeNewsWire

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments...

3 months ago - Accesswire

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tre...

4 months ago - GlobeNewsWire

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tre...

4 months ago - GlobeNewsWire

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states

6 months ago - GlobeNewsWire

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

SOLANA BEACH, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat...

6 months ago - GlobeNewsWire

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

$12.9 Million in Cash and Investments as of September 30, 2023; Runway Expected to Reach Meaningful Development Milestones

6 months ago - GlobeNewsWire

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat...

6 months ago - GlobeNewsWire

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat...

7 months ago - GlobeNewsWire

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat...

8 months ago - GlobeNewsWire

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...

9 months ago - GlobeNewsWire

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

SOLANA BEACH, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tre...

9 months ago - GlobeNewsWire

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...

9 months ago - GlobeNewsWire

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...

9 months ago - GlobeNewsWire

Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second Half of 2024 $14.0 Million in Cash and Investments as of June 30, 2023; Cash Runwa...

10 months ago - GlobeNewsWire

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy New data demo...

11 months ago - GlobeNewsWire

Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11

SOLANA BEACH, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...

11 months ago - GlobeNewsWire

Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium

Former Awardee and Artelo Employee, Professor Saoirse O'Sullivan will Present the 2023 Recipient with the Award Former Awardee and Artelo Employee, Professor Saoirse O'Sullivan will Present the 2023 R...

11 months ago - GlobeNewsWire

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies for Chemotherapy-Induced Neuropathy and Diabetic Neuropathy

11 months ago - GlobeNewsWire

Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium

ART12.11, a novel and patented cocrystal of CBD reverses the impact of chronic stress on outcomes of anxiety, depression, sociability and cognition

11 months ago - GlobeNewsWire